Atezolizumab for relapsed/refractory extranodal NK/T-cell lymphoma: the phase II NCCH1903/ATTACK trial - PubMed
3 hours ago
- #PD-L1 biomarkers
- #Atezolizumab
- #NK/T-cell lymphoma
- Atezolizumab monotherapy was evaluated in a phase II trial (NCCH1903/ATTACK) for relapsed/refractory extranodal NK/T-cell lymphoma (ENKTL), a rare disease with limited treatment options.
- The objective response rate (ORR) assessed by an independent review committee was 54% (7/13 patients), including 31% complete responses, with a median response duration not reached after 24.9 months of follow-up.
- Median progression-free survival was 2.4 months and median overall survival was 10.3 months, indicating clinically meaningful efficacy and durable responses.
- Structural variations in PD-L1 were detected in 36% of evaluable patients, correlating with a higher ORR of 75%, compared to 43% in those without such variations.
- PD-L1 expression via immunohistochemistry was positive in 45% of evaluable patients, with an ORR of 80% in this group versus 33% in PD-L1-negative patients, suggesting PD-L1 alterations and expression as potential biomarkers.